JP2024524631A - 炎症性疾患の治療 - Google Patents

炎症性疾患の治療 Download PDF

Info

Publication number
JP2024524631A
JP2024524631A JP2024501536A JP2024501536A JP2024524631A JP 2024524631 A JP2024524631 A JP 2024524631A JP 2024501536 A JP2024501536 A JP 2024501536A JP 2024501536 A JP2024501536 A JP 2024501536A JP 2024524631 A JP2024524631 A JP 2024524631A
Authority
JP
Japan
Prior art keywords
compound
inhibitors
per day
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524631A5 (enExample
Inventor
ダオ ジャスティン
アレクサンドル ガリアン ルネ
ヨンコヴァ ペトコヴァ マグダリーナ
アレクサンダー シーメイヤー クリスチャン
ハロ エドワール
ルエダ リンコン ナタリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2024524631A publication Critical patent/JP2024524631A/ja
Publication of JP2024524631A5 publication Critical patent/JP2024524631A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2024501536A 2021-07-12 2022-07-11 炎症性疾患の治療 Pending JP2024524631A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21305971 2021-07-12
EP21305971.0 2021-07-12
EP22315039.2 2022-02-24
EP22315039 2022-02-24
PCT/EP2022/069362 WO2023285405A1 (en) 2021-07-12 2022-07-11 Treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2024524631A true JP2024524631A (ja) 2024-07-05
JP2024524631A5 JP2024524631A5 (enExample) 2025-07-17

Family

ID=82748704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501536A Pending JP2024524631A (ja) 2021-07-12 2022-07-11 炎症性疾患の治療

Country Status (9)

Country Link
US (1) US20240325404A1 (enExample)
EP (1) EP4370128A1 (enExample)
JP (1) JP2024524631A (enExample)
KR (1) KR20240035480A (enExample)
AU (1) AU2022310901A1 (enExample)
CA (1) CA3225221A1 (enExample)
IL (1) IL309946A (enExample)
MX (1) MX2024000517A (enExample)
WO (1) WO2023285405A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020537672A (ja) * 2017-10-20 2020-12-24 ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. 炎症性障害の治療のための新規化合物及びその医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020537672A (ja) * 2017-10-20 2020-12-24 ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. 炎症性障害の治療のための新規化合物及びその医薬組成物

Also Published As

Publication number Publication date
AU2022310901A1 (en) 2024-02-22
MX2024000517A (es) 2024-01-31
EP4370128A1 (en) 2024-05-22
US20240325404A1 (en) 2024-10-03
KR20240035480A (ko) 2024-03-15
IL309946A (en) 2024-03-01
WO2023285405A1 (en) 2023-01-19
CA3225221A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
TWI902129B (zh) 給予kras抑制劑治療癌症
TWI883107B (zh) 用於復發型多發性硬化症的治療性酪胺酸激酶抑制劑
US20230346820A1 (en) Methods and compositions for the treatment of sars-cov-2
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20240307398A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
TW201628622A (zh) Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
CN111053768A (zh) 用于治疗黑素瘤的药物组合
WO2021216814A1 (en) Btk inhibitors to treat pulmonary distress in covid-19 patients
JP2020143068A (ja) 組み合わせ療法
KR20260042485A (ko) 궤양성 대장염의 치료를 위한 오베파지모드
CN116473973A (zh) 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
CN114746094A (zh) 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法
CN117677387A (zh) 炎性疾病的治疗
WO2023161326A1 (en) Compound for use in and methods of treatment of inflammatory diseases
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
US20240325404A1 (en) Treatment of inflammatory diseases
WO2025103408A1 (zh) 治疗alk阳性或ros1阳性的非小细胞肺癌的方法
CN114728003A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
WO2023161327A1 (en) Compound for use in and methods of treatment of inflammatory diseases
KR20250095627A (ko) 에스트로겐 수용체-매개 장애의 치료 방법
WO2024015506A1 (en) Methods of treating estrogen receptor-mediated disorders
Bahoosh et al. Proposed Pharmacological Treatments for COVID-19: Previously Confirmed Drugs
WO2023230288A1 (en) Methods and compositions for treating cancer
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN115666565A (zh) 用于治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250708

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260806